Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | BRAF | P15056 | 6/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199786 | 0.91 | KDR (0.51) | KDRBRAFFGFR1LTA4HHTR2A | |
| SCHEMBL10200860 | 0.89 | KDR (0.52) | KDRBRAFFGFR1LTA4HHTR2A | |
| SCHEMBL545790 | 0.88 | KDR (0.52) | KDRBRAFFGFR1LTA4HHTR2A | |
| SCHEMBL5423110 | 0.88 | KDR (0.54) | KDRBRAFFGFR1LTA4HHTR2A | |
| SCHEMBL545158 | 0.87 | KDR (0.42) | KDRBRAFFGFR1LTA4HHTR2A | |
| SCHEMBL5425709 | 0.87 | KDR (0.55) | KDRBRAFFGFR1LTA4HHTR2A | |
| SCHEMBL10200858 | 0.87 | KDR (0.55) | KDRBRAFFGFR1LTA4HHTR2A | |
| SCHEMBL5422272 | 0.86 | KDR (0.53) | KDRBRAFFGFR1LTA4HHTR2A | |
| SCHEMBL545035 | 0.85 | KDR (0.70) | KDRBRAFFGFR1JAK2SRC | |
| SCHEMBL545259 | 0.84 | BRAF (0.46) | KDRBRAFKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | KDR 1264/4885BRAF 215/4885FGFR1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.